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Abstract: An intrinsic clindamycin-resistant Enterococcus faecalis, the most common single species
present in teeth after failed root canal therapy, often possesses acquired tetracycline resistance.
In these cases, root canal infections are commonly treated with Ledermix® paste, which contains
demeclocycline, or the new alternative endodontic paste Odontopaste, which contains clindamycin;
however, these treatments are often ineffective. We studied the killing activity of the cyclic
antimicrobial peptide gramicidin S (GS) against planktonic and biofilm cells of tetracycline-resistant
clinical isolates of E. faecalis. The high therapeutic potential of GS for the topical treatment
of problematic teeth is based on the rapid bactericidal effect toward the biofilm-forming,
tetracycline-resistant E. faecalis. GS reduces the cell number of planktonic cells within 20–40 min
at a concentration of 40–80 µg/mL. It kills the cells of pre-grown biofilms at concentrations of
100–200 µg/mL, such that no re-growth is possible. The translocation of the peptide into the cell
interior and its complexation with intracellular nucleotides, including the alarmon ppGpp, can explain
its anti-biofilm effect. The successful treatment of persistently infected root canals of two volunteers
confirms the high effectiveness of GS. The broad GS activity towards resistant, biofilm-forming
E. faecalis suggests its applications for approval in root canal medication.
Keywords: gramicidin S; Enterococcus faecalis; tetracycline resistance; biofilms; root canal infections;
alarmone ppGpp; polymyxin B
1. Introduction
Teeth with necrotic pulps and periapical radiolucencies indicate the presence of bacteria in
a root canal system. They can cause apical periodontitis, an inflammatory process around the apex
of a tooth root accompanied by bone resorption [1,2]. Root canal infections are characterized by
a wide variety of combinations of a few oral anaerobic bacteria, such as Actinomyces species and
peptostreptococci. The non-oral but environmental bacterium Pseudomonas aeruginosa is frequently
isolated from treatment-resistant cases because of its intrinsic multidrug resistance, including resistance
to tetracycline [3]. However, more and more evidence has been provided on the prevalence of
Enterococcus faecalis in teeth associated with a failed endodontic treatment of root canal infections [2,4–7].
The success rate for the re-treatment of teeth with E. faecalis is lower (66%) than the overall success rate
of re-treatment (75%) [8]. Previous studies reported about up to 77% prevalence of E. faecalis in teeth
with failed endodontic treatment [7]. E. faecalis can best adapt to and tolerate the conditions in the filled
root canal [6]. This facultative anaerobe is able to grow at 6.5% NaCl and temperatures up to 45 ◦C and
is even able to colonize dentine under alkaline pH and glucose starvation [9]. It has a remarkable ability
to avoid leukocyte-dependent antibacterial mechanisms and to utilize collagen within dentin, using this
Pharmaceuticals 2016, 9, 56; doi:10.3390/ph9030056 www.mdpi.com/journal/pharmaceuticals
Pharmaceuticals 2016, 9, 56 2 of 14
property for adhesion within the root canal [2]. A number of other virulence factors in E. faecalis, such as
a plasmid-encoded surface localized adhesion protein, gelatinase (metalloendopeptidase), a serine
protease, hemolysin, which is classified as a type A lantibiotic, and extracellular superoxide, permit
adherence and facilitate invasion [6]. The surface adherence of biofilms is significant in persistent
endodontic infections because it increases the difficulty of eliminating biofilms by conventional
treatment measures [10]. Although the conventional endodontic irrigant sodium hypochlorite (1%–6%)
exhibits more efficient elimination of E. faecalis biofilms in comparison to chlorhexidine, calcium
hydroxide, povidone iodine and ethylendiamintetraacetat [11,12], this intracanal medication was
found to have a limited action against bacterial biofilms [13].
Currently, there are no clinically available compounds that disassemble biofilms of E. faecalis,
although several antimicrobial peptides are in development, such as siamycin I, which affects quorum
sensing, as well as protegrin, and oritavancin that can damage the bacterial membrane [14]. Recently,
the use of the commercially available Ledermix® paste, which contains demeclocycline, or the new
alternative endodontic paste Odontopaste, which contains clindamycin, was reported to be ineffective
in the treatment of E. faecalis infections due to the natural clindamycin and acquired tetracycline
resistance of these bacteria [6,15]. Their dominance in nosocomial infections is based on their ability
to develop multidrug resistance via the acquisition of antibiotic resistance genes on plasmids or
transposons from other bacteria. Notably, surface aggregation facilitates the contact between the
cells, which leads to the exchange of plasmids that carry resistance. Approximately 70% of E. faecalis
isolates from primary endodontic infections showed a resistance to tetracycline [16]. In genomic
analysis, the tetracycline resistance genes tetM and tetL, as well as gelatinase, aggregation substance
and enterococcal surface protein genes, were detected in these E. faecalis isolates.
In this paper, we report the antimicrobial and anti-biofilm activity of the cyclic decapeptide
gramicidin S (GS) against tetracycline-resistant E. faecalis illustrated by two cases of successful treatment
of Ledermix®-resistant root canal infections using this peptide.
2. Results
2.1. Susceptibility of Tetracycline-Resistant E. faecalis to GS
According to the data of the Clinical and Laboratory Standards Institute [17], enterococci are
defined to be resistant to tetracycline if the minimum inhibitory concentration (MIC) values are
≥16 µg/mL and they are called susceptible at MIC ≤ 4 µg/mL. Table 1 shows the resistance of
the E. faecalis DSM 2570, which was isolated from urine and represents a quality control strain
for antimicrobial susceptibility testing [18], the WW4 cheese isolate and four tetracycline-resistant
clinical isolates, designated TRE1–TRE5. For comparison, the clinical root canal isolate WW6, which
is susceptible to tetracycline (MIC < 1 µg/mL) but forms robust biofilms (Figure 1A), was also
studied (Table 1). Tetracycline inhibits protein synthesis, and its action is therefore bacteriostatic.
GS is a bactericidal antibiotic peptide. As shown in Table 1, its MIC, minimum bactericidal
concentration (MBC), and minimum biofilm inhibitory concentration (MBIC90) are mostly in the
range of 8–16 µg/mL for all studied E. faecalis strains. This small difference between inhibitory and
bactericidal concentrations as well as the concentrations required for the inhibition of biofilm formation,
explains the great bactericidal activity of GS, which gives bacterial cells no chance to remain alive or to
respond to the stress caused by GS treatment.
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Figure 1. Anti-biofilm activity of GS. (A) When eight E. faecalis strains were compared using a crystal 
violet staining assay, the tetracycline-resistant clinical isolate TRE2 exhibited the strongest biofilm 
formation in all three nutrient media; (B1) SEM image of a TRE2 biofilm formed on a hydroxyapatite 
disk, which served as a control and as a starting point for antibiotic treatment; (B2) when B1 was 
incubated in TH broth, the biofilm is found to re-grow in a suspended form; (C1) SEM image of B1 
after treatment with 400 μg/mL demeclocycline, and (C2) re-growth of a biofilm in suspension; (D1) 
B1 after treatment with 400 μg/mL GS; and (D2) no biofilm re-growth was observed after treatment, 
even when only 200 μg/mL of GS were used in D1. Reproducible results were obtained in two 
independent experiments. The scale on the SEM images is 1 μm. 
Table 1. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and 
minimum biofilm inhibitory concentration (MBIC) of GS against E. faecalis. 
E. faecalis Strain 
Resistance/Susceptibility (μg/mL) to
Antimicrobial Activity of GS (μg/mL) 
Tetracycline Demeclocycline
MIC a MIC MIC MBC MBIC90 
DSM 2570 16 8 8 8 4–8 
TRE1 16 16 8 16 - 
TRE2 16 32 16 16 8–16 
TRE4 16 8 8 8 - 
TRE5 16 16 8 16 - 
WW4 64 16 8 16 - 
WW6 <1 <1 8 16 8–16 
a MICs, MBCs and MBICs were determined in at least in two independent experiments, each 
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only 200 µg/mL of GS were used in D1. Reproducible results were obtained in two independent
experiments. The scale on the SEM images is 1 µm.
Table 1. Mini u inhibitory concentration ( I ), ini u bactericidal concentration ( B ) and
ini u biofil inhibitory concentration ( BIC) of S against E. faecalis.
E. faecalis Strain
Resistance/Susceptibility (µg/mL) to
Antimicrobial Activity of GS (µg/mL)Tetracycline Demeclocycline
MIC a MIC MIC MBC MBIC90
DSM 2570 16 8 8 8 4–8
TRE1 16 16 8 16 -
TRE2 16 32 16 8–16
TRE4 16 8 8 8 -
TRE5 16 16 8 16 -
WW4 64 16 8 16 -
WW6 <1 <1 8 8–16
a MICs, MBCs and MBICs were determined in at least in two independent experiments, each performed in
triplicate. MBIC was determined only for the three best biofilm-formers (see Figure 1A).
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2.2. Time-Dependent Killing Effect of GS
The bactericidal activity of GS against E. faecalis strains over time was studied in killing assays.
For this experiment, we used stationary cultures, which contained metabolically inactive, slow- or
non-dividing dormant cells that tolerate conventional antibiotics and cause persistent infections [19].
At the time points of 20 min and 40 min after the addition of GS, the undiluted 100-µL bacterial aliquots
revealed no colonies on agar plates. This indicates a prompt and complete reduction of the cell number
in planktonic suspension, which contained 108 CFU/mL cells (Figure 2). Notably, the metabolically
inactive dormant cells were also killed at the studied concentrations, which corresponded to the
5 × MIC and 10 × MIC values (Table 1). The increase from 5 to 10 × MICs led to a decrease in killing
time from 40 to 20 min for the E. faecalis DSM 2570 and WW6. The same killing curve was observed at
5 × MIC values of GS for the best biofilm former, the tetracycline-resistant clinical isolate E. faecalis
TRE2. However, its effective concentration was 80 µg/mL because its MIC value was 16 µg/mL.
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Figure 2. Reduction of the number of E. faecalis bacteria during exposure to GS: (A) control strain 
DSM 2570; (B) cheese isolate WW4; (C) root canal isolate WW6; and (D–F) clinical 
tetracycline-resistant isolates TRE1, TRE2, and TRE4, respectively. The bacterial number remained 
unchanged in the controls (dotted lines), but decreased drastically during exposure to 5 × MIC of GS 
(solid lines). The dashed lines show the faster bactericidal effect of 10 × MIC for DSM 2570 and WW6 
strains; 10 CFU/mL was taken as the detection limit although no colonies were grown from 
undiluted sample. The standard deviations were calculated from at least two independent 
experiments. 
2.3. Biofilm-Killing Effect of GS 
For these experiments, it was necessary to determine the biofilm forming capacity of all E. 
faecalis isolates to choose the strongest biofilm formers and the most suitable medium. A standard 
crystal violet staining assay was applied to evaluate the mass of the biofilms that were pre-grown for 
24 h in 96-well microtiter plates (Figure 1A). 
The strongest biofilm growth was found to occur in the Todd Hewitt (TH) broth, which 
contains glucose. The Mueller Hinton (MH) broth and minimal medium were less suitable for 
biofilm formation. The biofilm-forming capacity of the control strain DSM 2570 was comparable 
with that of the tetracycline-resistant WW4 (cheese isolate) and the tetracycline-susceptible WW6 
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Figure 2. Reduction of the nu ber f . f li teria during exposure to GS: (A) control strain
DSM 2570; (B) cheese isolate WW4; (C) root canal is late WW6; and (D–F) clinical tetracycline-res stant
isolates TRE1, TRE2, and TRE4, respectively. The bacterial number remained uncha ged in the co trols
(dotted lin s), but decreased drastically during exposure to 5 × MIC of GS (solid lines). The dashed
lines show the faster bactericidal effect o 10 × MIC for DSM 2570 and WW6 strains; 10 CFU/mL was
taken a the detection limit although no colonies were grown from undiluted sample. The standard
deviations were calculat d from t least two i dep ndent experiments.
2.3. Biofilm-Killing Effect of GS
For these experiments, it was necessary to determine the biofilm forming capacity of all E. faecalis
isolates to choose the strongest biofilm formers and the most suitable medium. A standard crystal
violet staining assay was applied to evaluate the mass of the biofilms that were pre-grown for 24 h in
96-well microtiter plates (Figure 1A).
The strongest biofilm growth was found to occur in the Todd Hewitt (TH) broth, which contains
glucose. The Mueller Hinton (MH) broth and minimal medium were less suitable for biofilm
formation. The biofilm-forming capacity of the control strain DSM 2570 was comparable with that
of the tetracycline-resistant WW4 (cheese isolate) and the tetracycline-susceptible WW6 (root canal
isolate) (Table 1). The tetracycline-resistant clinical isolate E. faecalis TRE2 was the best biofilm former.
Scanning electron microscopy (SEM) showed that the cells in this biofilm completely covered the
surface of the hydroxyapatite disc (HAD) and were attached to the HAD nanoparticles (Figure 1B1).
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After exposure to 400 µg/mL of GS for 18 h, the cell morphology of E. faecalis TRE2 was drastically
altered (Figure 1D1) in comparison to the control or to the treatment with 400 µg/mL of demeclocycline
(Figure 1C1). The GS-treated cells decreased in size from 1 to 0.6–0.8 µm, the cell surface got wrinkled,
and the cells detached from the HAD particles (Figure 1D1). Treatment of the pre-grown biofilms with
400 µg/mL of GS led to a disappearance of the matrix layer and to a partial elimination of biofilm cells,
so that the nanoparticles of the HAD were clearly exposed underneath the cells. No re-growth of the
robust TRE2 biofilm in the fresh TH broth was observed, even when only 200 µg/mL GS has been
applied (Figure 1D2). This concentration represents the minimal biofilm bactericidal concentration
(MBBC) of GS against E. faecalis TRE2, because subsequent plating of this non re-grown culture on
nutrient agar did not reveal any viable cells. The control biofilm (Figure 1B2) as well as the biofilm after
demeclocycline treatment (Figure 1C2) were clearly found to re-grow in the fresh TH nutrient broth
after cultivation at 37 ◦C for 24 h. The second strongest biofilm former, the tetracycline-susceptible root
canal isolate E. faecalis WW6 (Figure 1A), did not exhibit re-growth after treatment with 400 µg/mL
demeclocycline, as expected due to its high susceptibility (see Table 1). We note, however, that the
MBBC of GS against this strain was even lower (100 µg/mL) (data not shown).
2.4. GS Penetration into the Bacterial Cells and Binding Affinity to Nucleotides
Microbiological assays helped to elucidate the complex action of GS at the cellular level.
To understand the anti-biofilm activity at the molecular level, we first studied the membrane-penetrating
ability of GS, in order to find out whether it has any access to intracellular targets. For comparative
fluorescent microscopy, we used the dye 5(6)-carboxy-fluorescein-N-hydroxysuccinimide ester (CFSE)
as a control, which cannot penetrate the cell membrane. To detect GS by fluorecscence microscopy,
the photo-switchable GS analog GS-sw(FP) was used, which possesses an intrinsic green fluorescence
upon irradiation with visible light [20]. The fluorescence image of E. faecalis TRE2 stained with CFSE
showed strong fluorescence of only the cell envelope (Figure 3A). On the other hand, bacteria that were
incubated with GS peptide for 30 min (Figure 3B) showed an even fluorescence internally. The same
result was obtained by staining the other E. faecalis strains (data not shown).
The access of cationic GS to the cytoplasm suggests that it may engage in electrostatic interactions
with intracellular anionic targets. A key target could be the alarmon ppGpp, which regulates biofilm
formation [21]. Indeed, the addition of ppGpp to GS at different molar ratios led to their co-precipitation
as a result of mutual binding. At ppGpp:GS ratios of 2:1, 1:1 and 1:2 (Figure 3C), floating white flakes
could be seen, suggesting the presence of large aggregates. A further excess of GS led to the formation
of a stable milky opalescent suspension, which contained smaller nano-rods (Figure 3D). 31P-NMR
analysis of the intrinsic ppGpp phosphate signals confirmed the binding and aggregation, as sharp
signals were observed only in the presence of low concentrations of GS (Figure 3E). The broadening
and disappearance of the 31P-NMR signals with excess peptide indicated the precipitation of the
alarmone/GS complex. Electron microscopy of the milky suspension at a molar ratio of ppGpp:GS 1:8
(Figure 3D) revealed the assembly of GS with ppGpp into nano-rods with 50 nm width and 200 nm
length. The ability of GS to bind to ppGpp and thus to deplete its free cytoplasmic pool may explain
the strong inhibition of biofilm formation by GS described above (see MBIC90 values in Table 1).
Notably, ppGpp is not the only possible intracellular target of GS. In the literature, complex
formation of GS with nucleic acids and adenosine phosphates has already been described [22,23].
Because the triphosphates GTP and ATP are utilized in the biosynthesis of ppGpp, their binding to
GS may further enhance the anti-biofilm effect of the peptide. Using the same 31P-NMR approach as
described above, we also compared the ability of several other phosphorus-containing nucleotides
to bind GS. Judged by the molar ratio at which the 31P-NMR signal disappeared (see Figures in
Supplementary Materials), the studied nucleotides exhibited GS binding affinities in the following
order: ADP < ppGpp < ATP = GTP < GDP. In particular, this means that the ppGpp precursors represent
even stronger complex partners for GS, and their binding to GS should additionally contribute to the
overall inhibitory and bactericidal effects in bacterial biofilms.
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staining with a fluorescent GS-sw(FP) analog, confirming that the peptide can translocate across the 
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equimolar ratios, and a stable opalescent suspension is formed when GS is in large (i.e. electrostatic) 
excess. (D) SEM showed that the aggregation ppGpp by GS led to the formation of short nano-rods 
of about 50 nm width and 200 nm length. (E) When GS was added to ppGpp at different molar ratios, 
the 31P-NMR signals of the latter disappeared successively. The pure ppGpp sample (1:0) is shown in 
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treatment was carried out in a standard way using irrigation with sodium hypochlorite. An 
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Figure 3. Translocation of GS into the cells and its binding affinity to the bacterial alarmon ppGpp.
(A) Green fluorescence of the E. faecalis cell envelope upon staining with the dye CFSE, which cannot
penetrate the cellular membrane. (B) Fluorescence throughout the interior of the cells is seen upon
staining with a fluorescent GS-sw(FP) analog, confirming that the peptide can translocate across the
cell membrane into the cytoplasm. (C) Co-precipitation of GS and ppGpp is seen to occur at roughly
equimolar ratios, and a stable opalescent suspension is formed when GS is in large (i.e., electrostatic)
excess. (D) SEM showed that the aggregation ppGpp by GS led to the formation of short nano-rods of
about 50 nm width and 200 nm l n th. (E) When GS was added to ppGpp at different molar ratios,
the 31P-NMR signals of the latter disappeared successively. The pure pG p sampl (1:0) is shown in
red. The scale on the fluorescent images is 5 µm.
2.5. Medication Reports
Case I of root canal infection: Molar 38 of a 59-year-old female patient (M.B.) was
percussion-sensitive and responded negative to cold testing with CO2 snow. The initial root canal
treatment was carried out in a standard way using irrigation with sodium hypochlorite. An intracanal
Ledermix® Paste dressing was administered. For the next six weeks, the tooth remained percussion
sensitive and painful, so the root canals were again treated in the same way for the next four weeks,
but the second treatment with Ledermix® Paste was also unsuccessful. The pain was stronger and
radiated into the ear and head. At the patient’s request, the tooth was medicated using a mixture
of the antimicrobial peptides GS and polymyxin B (PMB) at a molar ratio of 2:1. The powders were
co-dissolved in a drop of 50% ethanol and applied as an intracanal dressing with a temporary Cavit™
restoration. Alleviation of pain was experienced after one hour, and a positive healing effect was
noted. After a few weeks without symptoms the tooth was sealed, and in the following five years no
recurrence was observed.
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Case II of root canal infection: Decay in molar 36 of a 25-year-old male patient (M.B.’s son)
was observed by X-ray as a radiolucent spot in the pulp region (Figure 4A). Without treatment,
an irreversible pulpitis developed within six months. The root canals were treated in a standard way,
but a painful root canal infection appeared after two months. After the direct application of ~2 mg GS,
which was suspended in sterile isotonic saline, the pain receded within an hour, and the root canals





Figure 4. Molar 36 of a 25-year-old male patient before and after treatment. (A) The radiolucent area in
the X-ray image indicates decay. (B) The sealed root canals after treatment with GS. The red arrowheads
mark the decayed area and the sealed root canals, respectively.
3. Discussion
The cyclic decapeptide gramicidin S (S = ”Soviet”) was isolated by Gause and Brazhnikova
from soil bacilli and described in Nature and Lancet in 1944 [24,25]. The symmetric structure
of GS is a double-repeated sequence of five amino acids, which are arranged in an antiparallel
cyclic manner (cyclo[phe-Pro-Val-Orn-Leu]2) [26]. GS has an amphiphilic structure, consisting of the
cationic non-canonical amino acid ornithine and the hydrophobic Dphenylalanine, valine and leucine.
As pharmaceuticals, antimicrobial peptides generally exhibit some unfavorable properties, such as
instability, salt sensitivity, high cost of production, and a rather non-specific spectrum of activity,
including hemolytic effects [27]. GS, on the other hand, is a very stable peptide. Its cyclic structure and
the presence of the unusual amino acids ornithine and Dphenylalanine avoid the typical proteolytic
degradation by common proteases. Overall, GS has a high hemolytic activity, which limits its use
to topical applications, though the addition of polyethylene glycol has been shown to prevent its
hemolytic effects [28]. The production of GS via the fermentation of producing Aneurinibacillus migulanus
phenotypes [29] is less costly than the usual chemical synthesis of antimicrobial peptides of non-bacterial
origin. GS is approved as the bioactive agent in Grammidin®Neo, a lozenge used against sore throat
and mouth ulcers, produced by Russian JSC Valenta Pharmaceuticals. Notably, despite a long treatment
history, no clinical cases of bacterial resistance against GS have been reported [30].
The promising observation that GS does not lead to bacterial resistance can be attributed to
its ability to attack multiple targets in bacterial cells at the same time. The first target of GS
is the prokaryotic plasma membrane; therefore, the peptide possesses enhanced activity against
Gram-positive bacteria like Staphylococcus spp., Streptococcus spp., and Enterococcus spp. [31]. In
addition to depolarization, presumably via the formation of short-lived pores at sub-MICs [32], it
also inhibits the respiratory enzymes NADH dehydrogenase and cytochrome bd terminal oxidase in
the bacterial membrane [33], and it detaches several vital peripheral membrane proteins, namely the
cell-division regulator MinD, the Lipid II biosynthesis protein MurG, and cytochrome c [34]. Here, we
have shown that GS does not only interact with the bacterial membrane, which causes structural and
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functional damage as described above. In fact, it can also penetrate into the cytoplasm, where it can
bind to ppGpp, the intracellular regulator of biofilm growth [35], and to its precursors ATP and GTP, as
well as the energy metabolites ADP and GDP (Figures S1–S4 in the Supplementary Materials). These
new modes of activity broaden the spectrum of effects known so far for GS. It is especially important
to realize that this multifaceted activity profile provides GS with unique bactericidal properties toward
Gram-positive bacteria irrespective of their physiological state, virulence, resistance, tolerance and
phenotypic variation. Generally, the stationary phase of a liquid bacterial culture contains a population
of metabolically inactive non- or slow-growing reversible phenotypes, which are known as persister
cells. They are tolerant to conventional antibiotics, even at 100 × MIC [36], because these antibiotics
target only growing cells. The ability of GS to disrupt membrane function and to form complexes
with intracellular targets after its rapid penetration into the cell interior leads to a complete and rapid
killing. This was demonstrated in our killing assays of stationary cells (Figure 2), and in the biofilm
re-growth experiments with each of the selected three strongest biofilm forming strains of E. faecalis
(Table 1 and Figure 1).
The origin of E. faecalis in the root canal is unclear, as enterococci do not belong to the normal
oral microbial flora [7]. However, 77% of British-produced cheeses [37], 60% of French soft cheeses,
and 20% of mozzarella, feta and Swiss Tilsiter cheese [38], contain enterococci. A genetic analysis of
saliva, previously treated root canal samples, and of cheeses, using repetitive extragenic palindromic
(REP)-PCR, revealed nine E. faecalis genotypes in all specimens studied. The transitional colonization
of the oral cavity after the consumption of cheese may thus be a possible reason for the prevalence of
E. faecalis in root canal infections [37,38]. Tetracycline-resistant enterococcal or multispecies infections
may provoke treatment failure, requiring tooth extraction, if the therapy using an intracanal Ledermix®
paste dressing is applied [16]. Even if several bacteria cause the infection, a GS-containing dressing
would be an unsurpassable choice for successful treatment due to the broad-spectrum activity of
GS [30]. Although microbiological analysis was not performed in two above described medication
cases, a cure using GS alone and in combination with PMB has been successfully achieved. Recently,
we also reported that these two peptides exert a synergistic effect against multidrug-resistant strains
and against biofilms of P. aeruginosa [39]. In the treatment of root canal infections caused by this
pathogen, which is frequently isolated from treatment-resistant cases, we expect that the combination
of GS/PMB could play a very promising role. Remarkably, the pain-alleviating effect, which we
describe here for both medication cases, had been previously observed in Russian clinical trials as
a characteristic property only of GS but not of the related tyrothricin complex [40]—a peptide mixture
of the lineal gramicidin A and cyclic tyrocidines [41]. This unique property of GS should thus be highly
advantageous in the treatment of painful root canal infections.
Biofilm formation is a key virulence factor in the pathogenicity of persistent E. faecalis
infections [42]. Nutrients such as hemin, vitamin K and glucose enhance biofilm formation.
The tetracycline-resistant E. faecalis strain TRE2 was the best biofilm former amongst all clinical
isolates. The exposure of its pre-grown biofilm to an aqueous solution of GS showed a bactericidal
effect (no re-growth of biofilms was observed, and no viable cells were found in this culture upon
plating), and some drastic morphological alterations of the biofilm remnants were observed (Figure 3).
Our results thus highlight the promising potential of GS in the successful treatment of root canal
infections caused by tetracycline-resistant biofilms of E. faecalis. In persistent infections, these bacteria
can penetrate the cellular and tissue barrier and thereby present an imminent risk to human
health, causing further non-oral, life-threatening infections, such as bacteremia or endocarditis [6,43].
Therefore, the successful treatment of root canal infections and their prevention are vital tasks. GS alone
or in combination with PMB offers an opportunity to help patients with untreatable root canal
infections, to save their natural teeth and to avoid high prosthetic costs.
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4. Materials and Methods
4.1. E. faecalis Strains, Antibiotics and the Determination of the Minimum Inhibitory Concentrations
The control strain Enterococcus faecalis DSM 2570 (ATCC 29212) was purchased from the German
Collection of Microorganisms and Cell Cultures (DSMZ). The WW4 isolate from cheese and the root
canal isolate WW6 were a kind gift from William G. Wade (Department of Microbiology, King’s College
London, London, UK). The tetracycline-resistant clinical isolates TRE1-TRE5 were obtained from the
medical laboratory of Staber & Kollegen, Heilbronn, Germany.
GS was produced by fermentation, extracted from producer cells and HPLC purified as described
earlier [28]. Other antibiotics (tetracycline and demeclocycline hydrochlorides) were purchased form
Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).
The bacterial strains were maintained at −80 ◦C using a Cryobank™System (Mast Diagnostica,
Reinfeld, Germany). To refresh the bacterial cells, single beads were recovered in 10 mL BHI broth
(Becton, Dickinson and Co., Sparks, MD, USA) in an overnight incubation at 37 ◦C and 200 rpm, in the
50 mL culture flasks. Single colonies were obtained by streaking these cultures on BHI agar plates,
which were then stored at 4 ◦C. Subsequently, the colonies were used to inoculate 10 mL MH broth
(Becton, Dickinson and Co., Sparks, MD, USA) to an optical density (OD) of 0.02 at 550 nm, and the
cultures were grown overnight. The test cultures were prepared by inoculating 10 mL MH broth to
an OD550 of 0.2 with the overnight cultures and allowing them to grow until the bacteria reached
OD550 of 1–2 at 37 ◦C and 200 rpm. For inoculation, the test cultures were diluted immediately prior to
the experiment in MH broth to obtain final inoculation doses of 5 × 105 CFU/mL according to the
CLSI recommendations [17].
For the determination of the MIC, the standard broth microdilution procedure [18] was modified
to obtain the uniform medium concentration after the addition of antibiotic stock solutions dissolved
in sterile deionized water (tetracycline and demeclocycline) or in 50% ethanol (GS). Briefly, 50 µL of
the double-strength MH broth was added to the upper row of the 96-well microtiter plates (Nunclon™,
Nunc GmbH & Co., Wiesbaden, Germany). Next, 50 µL of the standard MH broth was added to the
remaining wells, including the columns for the ethanol control and the positive (without peptides)
and negative (sterility) controls. Addition of the antibiotic stock solutions (50 µL) to the upper wells
provided a standard medium concentration and the antibiotic concentration to establish a concentration
gradient. Once the two-fold dilution series of the antibiotic concentration was prepared according
to [44], the plates were inoculated with 50 µL of bacterial suspensions from the exponentially growing
culture to reach 5 × 105 CFU/mL. The plates were incubated for 22 h at 37 ◦C and 5% CO2 without
agitation. To examine bacterial growth, 20 µL of an aqueous 80 µM solution of the redox indicator
resazurin was added to each well. The plates were incubated for another 2 h at 37 ◦C. The respiration
activity was calculated for each well as the difference in the absorbance of resorufin at 570 nm
and resazurin at 600 nm using the microtiter plate reader FlashScan550 (Analytic Jena GmbH, Jena,
Germany) and the WinFlash program. Positive values indicated bacterial growth and allowed the
determination of the lowest peptide concentrations that inhibit bacterial growth. All results were
obtained from several independent experiments, and each was performed in triplicate.
4.2. Determination of the Minimum Bactericidal Concentration (MBC)
Determination of MBC was carried out directly after the MIC assay. The 10-µL samples of all
8 dilution rows of microtiter plates were spotted on the square agar plates and incubated overnight
at 37 ◦C and 5% CO2. The MBC was determined as the lowest concentration at which no bacterial
growth was observed on the two parallel spotted plates in several independent experiments.
4.3. Determination of the Minimum Biofilm Inhibitory Concentration (MBIC)
The MBIC leading to a 90% decrease in biofilm growth (MBIC90) was obtained using the
microdilution procedure in the same way as for the determination of MIC, but the inoculation of the
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wells was performed with bacterial cells from stationary cultures to reach 5 × 107 CFU/mL. In contrast
to the determination of MBIC for the peptide IDR-1018 in [21], we used TH broth as a medium,
which facilitated maximum biofilm growth (Figure 1A). After incubation at 37 ◦C and 5% CO2 without
agitation for 24 h, the planktonic cells were washed and the crystal violet staining method was applied
to evaluate the biofilm growth [45] under the different peptide concentrations. The results were
obtained from two independent experiments, and each was performed in triplicate.
4.4. Determination of the Biofilm-Forming Capacity of the E. faecalis Strains
Three nutrition media—TH broth, MH broth and minimal medium [21], containing 62 mM
potassium phosphate (pH 7.0), 7 mM ammonium sulfate, 2 mM MgSO4, 10 µM FeSO4, 0.4% glucose and
0.5% casamino acids—were used to determine the best biofilm formers and the medium that supported
the best biofilm growth. The central 6 × 3 wells separated by the empty columns in the 96-well
microtiter plates were filled with overnight bacterial suspensions of OD550 = 0.2 in three different
media and incubated at 37 ◦C and 5% CO2 without agitation for 24 h. The adherent biofilms were
washed, dried, fixed in methanol and dried again. The staining was carried out according to previously
described methods [45] in 100 µL of the 0.1% crystal violet solution for 20 min. The excess dye was
removed with water, and the wells were thoroughly dried. The dye absorbed by biofilms was dissolved
in absolute ethanol, and its absorption was evaluated in a microtiter plate reader at 595 nm.
4.5. Determination of GS Killing Activity
The killing activity of GS was monitored during the 60 min after exposure to GS concentrations of
5 × MIC and 10 × MIC if needed. The stationary cultures were diluted up to OD550 = 0.2 calculated
for 1.5 mL culture in MH broth, including the addition of GS stock solution. The 200-µL aliquots were
removed from the cultures, which were incubated in 4 mL culture tubes at 37 ◦C with agitation of
about 220 rpm, at 0 min, 20 min, 40 min and 60 min. For each time point, the culture samples were
diluted 1:10 in 900 µL MH broth and 100 µL of undiluted culture, and each dilution was spotted as
ten 10 µL on the agar plates according to the drop plate method [46]. After the incubation of the plates,
the bacterial growth was evaluated by the enumeration of colonies. The decrease in bacterial number
indicated the killing activity for the each time point.
4.6. Biofilms on HAD: Scanning Electron Microscopy and Re-Growth
The three best biofilm formers were grown on HAD (3D Biotek, NJ, USA), which served as
a tooth-like material. The discs were placed into the 24-well microtiter plates (Nunc GmbH & Co.,
Wiesbaden, Germany) and inoculated with a cell suspension from the overnight stationary cultures,
which were grown in TH broth and diluted to OD550 = 0.2. After 30 h growth at 37 ◦C without
agitation, biofilms on HAD were placed into solutions containing 50 µg/mL, 100 µg/mL, 200 µg/mL
and 400 µg/mL of GS, 400 µg/mL of demeclocycline, or 150 mM sodium phosphate buffer (SPB, pH 7.2)
for 18 h. After that, the biofilms on the HAD were washed in SPB and placed into 1 mL of fresh TH
broth to examine their re-growth. Cultures were incubated at 37 ◦C with agitation at 200 rpm for 24 h.
To determine the number of viable cells after exposure to GS, the 100 µL of TH culture after re-growth
experiment were spotted as described in 4.5. The second series of biofilms on HAD after the treatment
were washed in SPB, fixed for 1 h in 2% glutaraldehyde dissolved in SPB, washed twice in distilled
water and dried in the sample box. The samples were sputtered to obtain a 1-nm platinum layer
using the high vacuum coating system Leica EM MED020 (Leica Microsystems, Wetzlar, Germany).
The biofilm images were obtained with a Supra 55 VP scanning electron microscope (Carl Zeiss,
Ostfildern, Germany).
4.7. Fluorescence Microscopy
The fluorescence of the photo-switchable analog GS-sw(FP), described previously [20], was used
to study GS translocation into the bacterial cytoplasm. Approximately 1 mL of the E. faecalis cell
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suspension adjusted to OD550 = 1.0 was co-incubated with 100 µg/mL of GS-sw(FP) in less active
closed-ring form and incubated at 37 ◦C for 30 min without agitation. To observe the fluorescence this
form was converted to the fluorescent open-ring form upon the irradiation with visible light directly
under the microscope for 5 min. The CFSE dye (Sigma-Aldrich, St. Louis, MO, USA), which cannot
penetrate the cell membrane, was applied for comparison. The bacterial suspension for this staining
was resuspended in the fresh 150 mM NaHCO3 buffer (pH 8.3). This was necessary because at this pH,
the amino groups of membrane proteins remain deprotonated and can better bind to CFSE. The dye
concentration used for the cell staining was 1 µL/mL (stock solution 10 mg/mL in DMSO). The staining
procedure was carried out at the same conditions (37 ◦C, 30 min, without agitation). The fluorescence
was observed using a Axioskop 40 light microscope (Carl Zeiss Light Microscopy, Göttingen, Germany)
equipped with an “A-Plan” objective (100x/1.25 Ph3), a fluorescence filter (type 09, λex 450–490,
λem 515) and a digital camera (PowerShot G5, Canon, Tokyo, Japan). The sensitivity setting ISO 50 was
used in experiments with the highly fluorescent CFSE dye. Due to the low fluorescence quantum yield
of GS-sw(FP), the sensitivity setting was increased to the ISO 400.
4.8. 31P-NMR Spectroscopy of GS with Nucleotides in An Aqueous Environment
The ppGpp solution was purchased from TriLink BioTechnologies (San Diego, CA, USA), and the
nucleotides ATP, ADP, GTP, and GDP were purchased from Sigma-Aldrich (Munich, Germany). 600 µL
of 1 mM or 0.5 mM ppGpp solution in D2O (pH 7.2) were added to lyophilized aliquots of GS, yielding
0.5 mM, 1.0 mM, 2.0 mM, 4.0 mM and 8.0 mM for the end volume of 600 µL and thoroughly vortexed.
Each NMR sample was then allowed to remain without any perturbation at ambient temperature
for at least 2 h to allow precipitate formation. Proton-decoupled 31P-NMR spectra were acquired
on a Bruker AVANCE 400 MHz spectrometer (Bruker-Biospin, Rheinstetten, Germany), operating
at a 31P frequency of 161.974 MHz. The experiments were performed without temperature control
(room temperature) using a Bruker 5 mm BB-PABBO probe. A single pulse (30 degrees, 15 µs) using
a standard pulse sequence zgpg30 (Bruker library) was used. For 1H decoupling, a waltz16 decoupling
sequence (Bruker library) was used. A total of 3500 scans were accumulated for each spectrum with
an interpulse delay of 2 s. Spectra were processed with TopSpin 3.1 software (Bruker) using line
broadening of 5 Hz.
4.9. Medication of the Root Canal Infections
In Case I, lyophilized powders of 9.0 mg GS (1141.4 g/mol) and 5.5 mg PMB-sulfate (1385.6 g/mol)
were placed onto a glass slide, mechanically mixed with a spatula, and suspended by addition a 50 µL
droplet of 50% ethanol. In Case II, about 4 mg of GS powder were suspended by addition a 50 µL
droplet of sterile isotonic saline. A fraction of the resulting slurry was applied to the open root
canal as an intracanal dressing, employing standard filling instruments. The tooth was temporarily
restored by Cavit™. When a few weeks without pain had passed, both teeth were permanently sealed.
Both individual cases studies (of the first author and a family member) were carried out privately and
with full responsibility and awareness of the risks, as the only alternative would have been to have the
decayed tooth extracted. Both the participants in medication signed a “Note of patient consent”.
5. Conclusions
In this study, we have demonstrated the considerable therapeutic potential of GS, which can
be used for the treatment of root canal infections caused by tetracycline-resistant E. faecalis and
by any of its tenacious biofilm-forming strains. The rapid killing by GS is based not only on its
membrane-perturbing activity but also on further intracellular effects. The latter seem to involve the
ability of the peptide to cross the lipid bilayer and bind to anionic intracellular targets (e.g., the alarmone
ppGpp, and energetic nucleotides), as demonstrated here. The persistently infected root canals of
two patients have been successfully treated, exhibiting rapid pain-alleviating effects. The broad activity
spectrum of GS should thus be especially beneficial if the taxonomic status of the bacterial burden in
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root canals cannot be rapidly identified. For multispecies infections containing multidrug-resistant
P. aeruginosa, the combination with PMB can significantly promote the curing effect further. Therefore,
we recommend the approval of GS alone and/or as a complex with PMB for the treatment of persistent
tetracycline-resistant root canal infections.
Supplementary Materials: The following are available online at http://www.mdpi.com/1424-8247/9/3/56/s1,
Figure S1. Binding of ATP by GS; Figure S2. Binding of ADP by GS; Figure S3. Binding of GTP by GS; Figure S4.
Binding of GDP by GS.
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TRE tetracycline resistant enterococci
CFU/mL colony forming units per mL
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